Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Combining ixekizumab (Taltz) and tirzepatide (Zepbound) in patients with psoriatic disease and obesity may cut predicted 10-year cardiovascular risk by roughly 30% compared to ixekizumab alone. Data from the phase 3b TOGETHER-PsO and TOGETHER-PsA trials showed sweeping improvements in blood pressure, cholesterol, blood sugar, and body weight. The findings suggest that tackling both inflammation and metabolic risk together is key for this high-risk group.
Patients with psoriatic disease already carry elevated cardiovascular risk due to chronic systemic inflammation — and when obesity is added to the mix, that risk climbs even higher. New phase 3b trial data presented at the European Academy of Dermatology and Venereology (EADV) Congress suggest that combining ixekizumab (Taltz) with tirzepatide (Zepbound) could meaningfully change that trajectory.
Across both the TOGETHER-PsO (plaque psoriasis, n=274) and TOGETHER-PsA (psoriatic arthritis, n=271) trials, patients on combination therapy for 36 weeks saw dramatically better outcomes than those on ixekizumab alone — not just in skin and joint disease, but across a broad range of cardiometabolic markers.
By the Numbers:
Why it matters: Treating psoriasis alone doesn't fix underlying cardiovascular risk factors. This data makes a compelling case for a dual-pathway approach — targeting both inflammation and metabolic disease — to protect the long-term heart health of patients with psoriatic disease and obesity.
